Talon Private Wealth LLC Trims Stock Position in Amgen Inc. $AMGN

Talon Private Wealth LLC lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 53.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,434 shares of the medical research company’s stock after selling 1,652 shares during the period. Talon Private Wealth LLC’s holdings in Amgen were worth $519,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Tower View Wealth Management LLC grew its stake in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares during the last quarter. Evergreen Advisors LLC purchased a new stake in Amgen in the first quarter valued at approximately $37,000. Sfam LLC purchased a new stake in Amgen in the fourth quarter valued at approximately $38,000. Advocate Investing Services LLC acquired a new stake in Amgen during the 4th quarter worth $39,000. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Amgen during the fourth quarter worth about $44,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: A late-stage study found that combining Amgen’s Imdelltra with AstraZeneca’s Imfinzi significantly improved overall survival for patients with extensive-stage small-cell lung cancer. The results could expand Imdelltra’s use into earlier-line treatment and strengthen Amgen’s oncology growth prospects. AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
• Positive Sentiment: Analysts and financial commentators continue to highlight Amgen’s profitability, multi-billion-dollar revenue base, cash generation and growing dividend as advantages over loss-making biotechnology companies such as Revolution Medicines, CRISPR Therapeutics and Moderna. This supports the stock’s appeal to income-oriented and more defensive investors. Amgen vs. Revolution Medicines
• Positive Sentiment: TD Cowen maintained its Buy rating, while another analysis characterized the recent selloff as an opportunity. Amgen also announced a Phase 4 Repatha plaque study, potentially generating additional evidence for the cardiovascular drug’s long-term value. Amgen: Buy the Novartis-Driven Selloff
• Neutral Sentiment: Cantor Fitzgerald reaffirmed a Neutral rating, and Amgen’s Wells Fargo healthcare conference presentation offered investors additional management commentary but no clearly identified major guidance change. Cantor Fitzgerald Reaffirms Neutral Rating
• Negative Sentiment: Amgen sold off after Novartis reported disappointing results for its pelacarsen cholesterol trial. Although pelacarsen is not Amgen’s drug and differs mechanistically from Amgen’s olpasiran and Repatha, the failure raised broader concerns about cardiovascular drug development and temporarily pressured AMGN. Analysts have generally left their price targets intact. Amgen Falls as Novartis Trial Failure Clouds Cholesterol Drug Class
• Negative Sentiment: Unusually heavy put-option activity, with reported purchases far above average, signaled increased near-term hedging or bearish speculation. Investors are also monitoring declining Prolia and XGEVA sales from biosimilar competition and the margin pressure associated with funding MariTide. Amgen Drops on a Trial It Did Not Run

Amgen Stock Down 1.3%

AMGN opened at $377.35 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $447.03. The stock has a market capitalization of $204.01 billion, a P/E ratio of 23.45, a P/E/G ratio of 2.76 and a beta of 0.43. The business has a 50 day simple moving average of $400.37 and a 200-day simple moving average of $367.91.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts anticipate that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. Amgen’s dividend payout ratio (DPR) is 62.65%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AMGN. Cantor Fitzgerald reissued a “neutral” rating and issued a $400.00 target price on shares of Amgen in a report on Tuesday. UBS Group lifted their price objective on shares of Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Truist Financial boosted their price objective on shares of Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research report on Friday, June 5th. Finally, Robert W. Baird raised their target price on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus target price of $381.68.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by insiders.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases. The company uses biologic research, genetics and other advanced technologies to develop treatments intended to address significant unmet medical needs.

Amgen’s medicines include Enbrel for certain inflammatory diseases; Prolia and Evenity for bone-related conditions; Xgeva for complications associated with cancer and bone disease; Repatha for cardiovascular risk reduction; Otezla for inflammatory conditions; and Aimovig for migraine prevention.